Rhythm360 Therapy
3 Modes of Operation
- stopping AF before it starts, preserving heart
health, and transforming care for patients
-
MaxWell Biomedical, a leader in cardiac care innovation, is excited to announce a significant milestone: the receipt of a $1.86 million grant from the National Institutes of Health (NIH), complemented by investments from private investors.
This funding will accelerate the development of the MaxWell Biomedical Spatial Resynchronization Therapy (SRT) System, an innovative non-ablative technology designed to restore and maintain Functional Sinus Rhythm in patients with atrial fibrillation (AF).
AF, a condition linked to severe complications such as stroke and heart failure, results in over 450,000 hospitalizations and approximately 160,000 deaths annually in the U.S. The MaxWell SRT System employs cutting-edge ultra-low energy stimulation to non-ablatively terminate AF, restoring left atrial function, without the discomfort associated with traditional high-energy cardioversion.
Early trials have demonstrated the system's efficacy, with an impressive 83.3% success rate within 15 seconds and 100% success within 5-10 minutes.
The SRT System is set to revolutionize cardiovascular care.Successfully executing the NIH SBIR Phase II award will position the SRT System for Investigational Device Exemption (IDE) approval, paving the way for the clinical studies needed to secure Pre-Market Approval (PMA) for this transformative technology aimed at treating the growing population of patients with AF and heart failure.
Revolutionizing AF and HF Care with Rhythm360 Therapy
At MaxWell Biomedical, we're revolutionizing care for atrial fibrillation (AF) and heart failure (HF) with Rhythm360 Therapy—a pioneering, non-ablative solution specifically designed to address the unique challenges of managing both conditions.
Our innovative Spatial Resynchronization Therapy (SRT) combines advanced technology to prevent atrial fibrillation (AF), restore sinus rhythm (SR), and preserve left atrial function (LAF)—all without damaging heart tissue. Rhythm360 Therapy delivers these benefits through three transformative modes of action.
Preemptive Prevention: Proactively prevents AF by detecting early warning signs and delivering targeted pacing to stop episodes before they start.
Reactive Termination: If AF does occur, SRT transitions to its second stage: Imperceptible Spatial Resynchronization Therapy (SRT).
Restorative Cardioversion: In rare cases of persistent AF, the system escalates to low-energy, pain-free cardioversion to ensure effective rhythm restoration.
Designed with patients in mind, Rhythm360 Therapy addresses the unmet needs of those with severe, coexisting AF and HF, offering a safer and more effective path to improved outcomes and quality of life. MaxWell Biomedical is leading the charge in transforming cardiac care.
At the core of MaxWell’s solution is a sophisticated three-stage approach that redefines AF management (Rhythm360 Therapy)
Active Atrial Fibrillation Management
Device Approach Designed to Address AF History
Maximum Wellness
[ mak-suh-muhm ] [ wel-nis ]